<DOC>
	<DOCNO>NCT02419859</DOCNO>
	<brief_summary>The purpose study obtain assessment ( efficacy , safety , patient report outcome ) basal bolus insulin delivery PaQ insulin-using patient type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>A Study Assess Insulin Delivery With PaQ® Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This prospective , single center , open-label , uncontrolled study ass efficacy , safety , patient report outcomes insulin delivery PaQ® patient type 2 diabetes mellitus ( T2DM ) currently receive basal/bolus insulin therapy without oral anti-diabetic drug ( OADs ) glycemic control . The patient 's participation study comprise three phase : screening/baseline evaluation , transition PaQ use optimization , PaQ treatment period . The use phase allow orderly transition PaQ treatment well reliable construct interpret final data .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<criteria>Is least 18 year age ; Has clinical diagnosis T2DM , determine clinical history medication usage ; Has A1C ≥ 7.0 % ≤ 11.0 % ; Is treat basalbolus insulin therapy ( least 2 injection per day ) without OADs , and/or GLP1 agonist least 3 month change ( addition discontinuation exist drug change dose ) OADs last 8 week , ( See Section 7.4 definition baseline basal bolus therapy ) ; Determined investigator insulin requirement achieve glycemic target meet insulin capacity PaQ device ; If concomitant metformin , serum creatinine &lt; 1.5 mg/dL ( male ) &lt; 1.4 mg/dL ( female ) ; If female , childbearing potential , negative urine pregnancy test screening must use adequate mean contraception determine Investigator ; Is clinically euthyroid judged Investigator ; Is able understand sign require study document comply CIP requirement ; Is deem capable Investigator perform requirement CIP , include use PaQ , frequent selfmonitoring blood glucose . Is poorly compliant currently prescribe diabetes regimen , determine Investigator ; Is poorly compliant prescribe selfmonitoring blood glucose , determine Investigator ; Is currently take take sulfonylurea within last 2 month ; Has BMI great 40 kg/m2 ; Has experience recurrent severe hypoglycemia ( &gt; 2 episode ) require assistance past 6 month ; Has exist dermal irritation/inflammation abdominal area may interfere use PaQ , determine Investigator ; Has know clinically significant hypersensitivity skin adhesive ; Is female childbearing potential , pregnant , lactating , plan become pregnant ; Is currently treat expect require undergo treatment systemic steroid oral , intravenous , intramuscular route ( inhale low systemic exposure permit ) ; Currently abuse drug alcohol history abuse Investigator 's opinion would cause individual noncompliant ; Has receive investigational drug within 1 month ; Has donate blood within 30 day ; Has significant medical condition ( include current past history cardiovascular disease ) , laboratory finding , medical history Investigator 's opinion may affect successful completion study and/or personal wellbeing ; Is immediate family member ( spouse , parent , child , sibling ) personnel directly affiliate study investigative site , personally directly affiliate study investigative site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Insulin</keyword>
	<keyword>Continuous subcutaneous insulin infusion ( CSII )</keyword>
	<keyword>Insulin pump</keyword>
</DOC>